• Explore /
  • Poster
  • / A single-arm, phase II study of autophagy modulation using hydroxychloroquine in addition to encorafenib and cetuximab or panitumumab in metastatic BRAF-mutated colorectal cancer refractory to standard therapy.

A single-arm, phase II study of autophagy modulation using hydroxychloroquine in addition to encorafenib and cetuximab or panitumumab in metastatic BRAF-mutated colorectal cancer refractory to standard therapy.

Abstract Poster

Authors

Chetan Vakkalagadda

Chetan Vakkalagadda

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL;

Chetan Vakkalagadda , Sabeeha Mukit , Masha Kocherginsky , Sheetal Mehta Kircher , Aparna Kalyan , Mary Frances Mulcahy , Al Bowen Benson III, Navdeep Chandel , Devalingam Mahalingam

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS262)

DOI

10.1200/JCO.2023.41.4_suppl.TPS262

Abstract #

TPS262

Poster Bd #

P4

Abstract Disclosures

Similar Posters

First Author: Josep Tabernero

First Author: Enrique Sanz-Garcia

First Author: Andrew H. Ko

First Author: Yuki Matsubara